Trial Profile
The Compassionate Use of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary)
- Indications Pantothenate kinase-associated neurodegeneration
- Focus Adverse reactions; Expanded access
- Sponsors ApoPharma; Chiesi
- 01 Apr 2016 Status changed from suspended to recruiting, according to ClinicalTrials.gov record.
- 25 Dec 2015 New trial record